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Abstract 
The presence of depression in schizophrenia has been a challenge to the 
Kraepelinian dichotomy, with various attempts to save the fundamental distinction 
including evoking and refining diagnoses such as schizoaffective disorder. But the 
tectonic plates are shifting. Here we put forward a summary of recent evidence 
regarding the prevalence, importance, possible aetiological pathways and treatment 
challenges that recognising depression in schizophrenia bring. Taken together we 
propose that depression is more than co-morbidity and that increased effective 
therapeutic attention to mood symptoms will be needed to improve outcomes and to 
support prevention. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Depression and schizophrenia: cause, consequence or trans-diagnostic 
issue? 
 
Prevalence of Depression in the life course of Schizophrenia 
The prevalence of depressive disorder in schizophrenia has been reported to be 
around 40%, however the stage of illness (early vs. chronic) and state (acute or post-
psychotic) factors influences figures, which can thus vary considerably1.  In acute 
episodes rates are up to 60%, whilst in post-psychotic schizophrenia rates of 
moderate to severe depression vary between 20% in chronic schizophrenia and 50% 
following treatment of first episode2. When examining very early phases of illness, in 
groups identified as ultra high risk (UHR) for psychosis, high rates of  ‘co-morbid’ 
axis one diagnoses are reported, with over 40% reaching criteria for a depressive 
disorder, outweighing  anxiety or other mood symptoms3. When depression is 
investigated longitudinally in schizophrenia, the vast majority, up to 80%, of patients 
experience a clinically significant depressive episode at one or more time point 
during the early phase. This underlines how cross-sectional rates markedly 
underestimate the true prevalence and suggests that in the early phase of illness at 
least, mood symptoms may be more than ‘co-morbid’ experiences. The diversity in 
reported figures for depression is also partly attributed to the challenge in 
distinguishing mood symptoms from negative symptoms, suggesting a complex and 
as yet poorly understood overlap with other symptom dimensions at a 
phenomenological level4. Depression in schizophrenia has long been a taxonomic 
challenge leading to assertions that true schizophrenia is ‘non-affective’; or invention 
of new diagnoses and broadening definitions, such as schizoaffective disorder. In 
DSM-V schizoaffective disorder, the occurrence of the delusions or hallucinations 
must be present in the absence of any serious mood symptoms for at least 2 weeks 
whilst the mood disorder must be present for the majority of the total duration of 
illness5. Our increasing knowledge as to the prevalence and course of depression in 
schizophrenia particularly, in the early years makes, the distinction between 
schizophrenia and new definitions of schizoaffective disorder even more challenging 
2. 
 
Importance of depression in schizophrenia 
Historically there has been some thought that the presence of mood symptoms in 
schizophrenia may be a good prognostic indicator, with patients who have high 
levels of affective symptoms appearing more on the ‘bipolar’ rather than 
deficit/autistic end of a psychosis continuum model6. However on the contrary, 
evidence suggests that depression is linked to poorer outcomes in schizophrenia2, 7. 
As example, depression is the most significant factor in completed suicide in 
schizophrenia, more so than acting on command hallucinations8. Depression also 
has long term consequences for functional recovery and quality of life 1. Conley et al 
report that those with schizophrenia and depression were significantly more likely to 
relapse, to be a safety concern (violent, arrested, victimized, suicidal), have greater 
substance-related problems and report poorer life satisfaction, mental functioning, 
family relationships, and medication adherence1.  In UHR samples, reporting of 
psychotic like experiences in the presence of moderate depression also raises risk 
for suicidal ideation. Kelleher et al show in a large community sample that attenuated 
psychotic experiences were relatively common among young people who had a 
diagnosis of moderate depressive disorder, and that the combination of experiences 
in this sample was significantly associated with suicidal behavior: i.e. patients did not 
need to present with severe depression or have formal psychotic symptoms to be at 
heightened risk9. In addition, depression has been linked to increased risk of 
transition from UHR to FEP, suggesting that in this group depression also indicates a 
poorer outcome10. However, the relationships are not straightforward nor is there 
sufficient evidence to suggest direct causality. In longitudinal studies depression and 
positive symptoms may co-occur but not necessarily predict each other over time11. 
 
Phenomenology of depression in schizophrenia: interplay of depression and 
negative symptoms 
Depression is a mood disorder that is characterized by apathy, low mood and social 
withdrawal 12. Beck describes a ‘cognitive triad’ in depression of “life is pointless, the 
future hopeless and the self is worthless”13. The nature of the phenomenology of 
depression in schizophrenia, however, has not often been interrogated in 
phenomenological terms. Some of our recent evidence suggests self-stigma, shame, 
difficulty in regaining trust in ones own thoughts after recovery from delusional 
beliefs, and poor motivation are core features rather than other more ‘biological’ 
symptoms such as early morning wakening, diurnal variation in mood or loss of 
appetite14. The Calgary Depression Scale for Schizophrenia (CDSS) is widely used 
to assess depression as a distinct from negative symptoms, with weight resting more 
on subjective reports of hopelessness, guilt and suicidal ideation rather than 
agitation, anhedonia and paranoid symptoms as seen in other depression rating 
scales15.  
 
Use of the CDSS has been built on the distinction between primary and secondary 
negative symptoms.  Secondary negative symptoms (particularly those of such as 
anergia, alogia and flattened affect) may present as a result of depression16. 
However , there are features in common to both depression and negative symptoms, 
such as social withdrawal, diminished capacity to experience pleasure (anhedonia) 
and loss of motivation . With regard to anhedonia, recently there has been distinction 
between motivational anhedonia (motivation to pursue rewards) and consummatory 
anhedonia (pleasure experienced in anticipation or response to rewards). 
Consummatory anhedonia and difficulty in anticipating future pleasure may be more 
in keeping with depression, where as motivational anhedonia better seen as a 
primary negative symptom. Strauss  and colleagues argue that anhedonia should not 
defined as a diminished capacity to experience pleasure but a cognitive dissonance 
of low pleasure that surfaces when a person is asked to report on future or past 
positive emotions, reduced pleasure seeking behavior or elevation of negative 
emotions17. This has strong similarities with depression at a symptom level (negative 
emotions associated with difficulty in retrieval of positive emotions or memories) and 
within the NIHR RDoC framework suggests the need to investigate anhedonia at a 
symptom level across diagnoses.  
 
Thus, whilst anhedonia may be common to depression and negative symptoms, 
other core depressive symptoms, as assessed with the CDSS appear distinct. We 
have previously shown depression and negative symptoms as specifically assessed 
are orthogonal2. This leads to the possibility that whilst anhedonia itself may be 
considered transdiagnositc, subtypes including anticipatory, consummatory and 
motivational anhedonia, maybe more specific. 
 
 
Depression and mood instability as a dimension of psychosis. 
Of the many factor analysis studies of psychosis, all identify depression and more 
broadly mood symptoms as a distinct dimension, including those that investigate a 
schizophreniform sample in the absence of affective psychoes18.  We note above the 
high rates of depression in UHR and first episode samples but importantly, instability 
of mood in the early course of psychosis is also widespread. Instability in mood and 
negative affect is associated with clinical and nonclinical paranoid thinking and with 
the emergence and persistence of auditory hallucinations19. It also explain new 
inception of paranoid ideas and auditory hallucinations at 18 months20. High rates of 
childhood trauma are reported in both schizophrenia and depression compared to 
controls  and are thought to be important in the genesis of both disorders21. Mood 
instability may act as a mediator between traumatic events such as bullying and 
persecutory ideation as well as childhood sexual abuse and psychosis, though 
interestingly this effect doesn’t hold true at the point of transition in UHR samples22.  
 
Psychotic-like experiences are also more common in individuals with anxiety and 
depressive disorders, while UHR samples have high rates of anxiety as well as  
depression23. Why mood instability levels are high in schizophrenia or how this 
relates to depression in this group requires further research, but the mechanism may 
involve maladaptive cognitive emotional regulation strategies involving situation 
selection, rumination, worry, re-appraisal and experiential avoidance. For example 
experience sampling method (ESM) studies demonstrate patients with schizophrenia 
are more stress reactive than first degree relatives or healthy controls, and this 
emotional reactivity correlates with positive symptoms and need for care24.  
 
The close linkage between psychosis symptoms and depression, especially in the 
prodromal phase has led to proposals that depression in schizophrenia may be the 
severe end of a dimension of affective dysregulation beginning in adolescence 
progressing into the early stages of psychosis as the illness crystalizes. Fusar-poli 
and Yung propose an increasing specificity and power of positive symptoms 
whereby at a population level both may be non significant co-occurrences, yet when 
seen in established severe mental illness have distinct specificity25. It is possible the 
relationship between mood and positive symptoms follow a similar course; thus 
when seen in UHR may represent non-specific indicator of pluripotent pathways, yet 
as illness progression occurs a more direct relationship is possible. Indeed with 
affective disorders, psychotic symptoms are understood to arise when mood 
symptoms are most severe, for example in psychotic depression, yet they often co-
occur at population level and in UHR samples in a manner not specific to diagnostic 
categories9  
 
Three pathways to depression in schizophrenia. 
How are we to understand this varied picture of depression in schizophrenia? 
Birchwood argued that there are three distinct pathways: depression which is 
intrinsic to psychosis, depression which is a psychological reaction to  the diagnosis 
and its implications for social status and position, and depression as ‘smoking gun 
evidence’ of historical childhood trauma 26. This framework seems to have stood the 
test of time. Trauma, neglect and social adversity are now well established risk 
factors for schizophrenia27. These factors also share risk for a variety of other 
disorders (including depression itself) and for this reason depression may be trans-
diagnostic.  We have published a series of studies examining the second pathway2, 
26, 28-31. The summary is that it is the way a person appraises the meaning and 
significance of their psychotic experience, including their subordinate relationship to 
voices, or persecutors and the impact of the diagnosis on social status that underlies 
the development of depression. We have shown that this is the case even during the 
acute phases of illness where insight is not totally lost2, 26. Therefore, of Birchwood’s 
three pathways it is the first, depression as intrinsic to psychosis itself, that may now 
need further exploration. 
 
If we move to accept that depression, for some at least, is intrinsic in part to the 
disorder itself, the question arises as to whether this occurs as part of a Fould’s 
hierarchy, whereby patients exhibiting symptoms at a given level must also display 
symptoms at each of the lower levels32, whether depression a manifestation of their 
common aetiological factors, or indeed if there may be a more causal relationship. 
Recent evidence shows that first episode schizophrenia and first episode affective 
psychosis have similar changes in brain structure, although progressive insular grey 
matter loss may me more pronounced in schizophrenia33. Increase in stress 
reactivity seen in schizophrenia may be linked to inflammatory and structural brain 
changes24. Hippocampal grey matter volume (GMV) reduction is found in unipolar 
depression, related to the duration of illness34 but is also seen in schizophrenia. 
Inflammation mediated effects on Brain derived neurotrophic factor (BDNF) is a 
proposed pathway for this effect35. There is evidence that changes in circulating 
inflammatory markers and neurotrophins associated with the onset of depression are 
also seen commonly in schizophrenia36, with evidence that the presence 
schizophrenia and depression being specifically toxic;  Noto recently demonstrated 
that IL-6, IL-4, IL-10 and TNFα were significantly higher in this  patient group37. In 
addition, recent studies by Chuang et al show that in depression, blunted affect, 
alogia and withdrawal are inversely associated with grey matter volume in the 
bilateral cerebellum whilst in schizophrenia, anhedonia, and avolition are inversely 
related to white-matter volume in the left anterior limb of internal capsule and 
positively in the left superior longitudinal fasciculus and key areas involved in the 
processing of reward anticipation38. In functional brain imaging, patients with 
depression and schizophrenia show similarly enhanced brain response to fearful 
facial expressions, particularly in the thalamus, to those with affective psychosis39. 
Regions critical to emotional processing are common in models of psychotic 
symptoms and include the hippocampus, insula and prefrontal cortex. These areas 
are implicated in both depression with psychosis and schizophrenia40. In broader 
terms of affective instability, there is some convergence of evidence that alterations 
in amygdala activation is involved in difficulty in emotional processing, salience to 
emotional stimuli, and behavioural response23. 
 
Thus it is possible that depression (as a core dimension of psychosis) not only 
explains some of the commonality in biological findings across mood disorders and 
schizophrenia, but provides potential aetiological pathways. This may be particularly 
relevant when the most active illness process is ongoing i.e. during the early critical 
period when disease trajectories are set. We might suggest that depression drives 
forward further symptom dimensions through a stress-inflammation-structural brain 
change pathway. This area is ripe for further investigation. 
 
Treatment of depression.  
Even though depression in schizophrenia is increasingly recognised as a dimension 
of schizophrenia psychopathology, clinically it remains inadequately treated41. More 
than fifteen years have passed since Siris published “Depression in the era of 
atypical antipsychotic agents’ with the recommendation that antipsychotic dose 
reduction or changing to a atypical antipsychotic may reduce the occurrence of 
depression42. Yet the prevalence of depression in schizophrenia has remained high, 
and rates of suicide unaltered, despite the wide use atypical antipsychotics, 
suggesting more treatment options are needed.  
 
Targeting the treatment of depression in early psychosis has the potential to reduce 
suffering, risk of suicide and improve functional outcome, yet the extent of the 
effectiveness of existing treatments for depression in the context of schizophrenia is 
unclear. CBT and anti-depressants are recommended in the treatment of unipolar 
depression and, in the recent update of the UK NICE guidelines for schizophrenia it 
is recommended this guidance be adhered to43; however, there is very little evidence 
for this assertion. Despite their frequent use on a pragmatic basis, there have been 
few sufficiently powered, randomised controlled trials of antidepressants for the 
treatment of depression in schizophrenia, although recent meta-analysis gives some 
limited evidence of effect44. Cognitive behavioural therapy for psychosis (CBTp) has 
been the subject of much research in recent years, however has primarily focused 
on effectiveness for positive symptoms, transition from high risk status and more 
recently on distress. No CBTp studies have used depression as a primary outcome 
or target of therapy. The pervasive presence of depression in schizophrenia and 
early phase psychosis, and the proposed role of affect dysregulation in the 
development of emerging psychotic thinking on the one hand and quality of life in 
established psychosis on the other, underlines the urgent need for treatment trials. 
We cannot assume that ‘standard’ pharmacological interventions or CBT for 
depression or would be effective. For example, as we have reviewed above, the 
content of depressive thinking in psychosis can include internalised stigma and 
entrapment by psychosis and intervention might therefore need to be augmented by 
practical steps to achieve mastery of the illness or of emancipating the individual 
from corrosive stigmatising stereotypes2, 28. 
 
Conclusion 
There are probably several pathways to depression in schizophrenia, some of which 
are well understood. Depression in schizophrenia challenges a categorical and 
hierarchical diagnostic system. If we accept depression in schizophrenia is common, 
as our evidence would indicate, what are the implications for psychotic depression or 
schizoaffective disorder as diagnostic categories? This is open for debate, however, 
it is clear that the concept of depression as a comorbidity of schizophrenia is a 
misnomer; its role may well be much more profound. Depression is now recognized 
as occurring frequently in schizophrenia particularly as it develops in adolescence. It 
is significant in the prediction of transition to FEP, poor clinical outcomes, quality of 
life and suicide1, 7, 8, 25.  Yet all this has not been translated into commensurate 
clinical recognition and to the resolution of uncertainties in therapeutic approaches. 
First episode psychosis sees the highest rate of decline in functioning, and high rates 
of depression, yet conversely it is a period of high level of recovery from positive 
symptoms. This underlines the need for focused interventions outwith positive 
symptoms. The interplay of depression and mood instability with the emergence of 
delusions and hallucinations, opens up the prospect of trials targeting affective 
dysregulation and mood instability as a preventive maneuver. The current lack of 
evidence for the treatment of depression in schizophrenia is the result of a lack of 
sufficient investigation, rather than lack of evidence of effect, and may result in a 
potential missed opportunity for effective intervention with potentially wide 
consequences for the illness and its prevention. Trials of routine treatments for 
unipolar depression, with vs without adaption for the schizophrenia context should 
feature high on funders’ research priorities as this holds the hope of a significant 
impact on recovery, reducing levels of completed suicide and patient suffering.  
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